RT Journal Article
SR Electronic
T1 Epidemiology, clinical presentation and management of COVID-19 associated Mucormycosis: A single center experience from Pune, Western India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.15.21263622
DO 10.1101/2021.09.15.21263622
A1 Dravid, Ameet
A1 Kashiva, Reema
A1 Khan, Zafer
A1 Bande, Balasaheb
A1 Memon, Danish
A1 Kodre, Aparna
A1 Potdar, Prashant
A1 Mane, Milind
A1 Tamboli, Asir
A1 Pawar, Vishal
A1 Patil, Dattatraya
A1 Banerjee, Debashis
A1 Bhoite, Kailas
A1 Shinde, Akshay
A1 Pharande, Reshma
A1 Kalyani, Suraj
A1 Raut, Prathamesh
A1 Bapte, Madhura
A1 Saldanha, Charlotte
A1 Chandak, Dinesh
A1 Ajani, Fouzia
A1 Mehta, Anshul
A1 Reddy, M Sateesh
A1 Bhayani, Krushnadas
A1 Laxmi, S S
A1 Vishnu, P D
A1 Srivastava, Shipra
A1 Khandelwal, Shubham
A1 More, Sailee
A1 Shakeel, Atif
A1 Pawar, Mohit
A1 Nande, Pranava
A1 Harshe, Amol
A1 Kadam, Sagar
A1 Hallikar, Sudhir
A1 Kamal, Nudrat
A1 Andrabi, Danish
A1 Bodhale, Sachin
A1 Raut, Akshay
A1 Gawande, Pushkar
A1 Bhandari, Ankush
A1 Wasmatkar, Nilesh
A1 Sarkar, Adnanali
A1 Chandrashekhar, Sangeeta
A1 Butiyani, Pallavi
A1 Akhade, Geetanjali
A1 Abnave, Aditi
A1 Raman, Chandrashekhar
A1 Basade, Siraj
A1 Mahajan, Uma
A1 Joshi, Gaurav
A1 Mane, Dilip
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263622.abstract
AB Background The second COVID-19 wave in India, triggered by the Delta variant,has been associated with an unprecedented increase in cases of COVID-19 associated Mucormycosis(CAM), mainly Rhino-orbito-cerebral mucormycosis(ROCM).The primary reason appears to be an unusual alignment of multiple risk factors in patients like prevalence of hypoxia, uncontrolled diabetes mellitus, indiscriminate use of steroids, high iron levels and immune dysfunction.Methods This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, Western India between 1st April 2020 and 1st August 2021 to identify patients admitted with CAM. The primary endpoint was incidence of all cause mortality due to CAM. Secondary outcomes studied were need for mechanical ventilation and intensive care unit(ICU) admission. Baseline and time dependent risk factors significantly associated with death due to CAM were identified by Relative risk estimation.Results 59 patients were diagnosed with Mucormycosis at NHRC (58 ROCM, 1 Renal (disseminated) mucormycosis). Median age of the cohort was 52(IQR: 41,61) years and it included 20.3% females. Median duration from first positive COVID-19 RT PCR test to diagnosis of Mucormycosis was 17(IQR: 12,22) days. 90% patients were diabetic with 30% being newly diagnosed at the time of COVID-19 admission and 89% having uncontrolled sugar level (HbA1c > 7%). All patients were prescribed steroids during treatment for COVID-19. 56% patients were prescribed steroids for non-hypoxemic, mild COVID (irrational steroid therapy) while in 9%, steroids were indicated but were prescribed in inappropriately high dose. Majority of the patients were treated with a combination of surgical debridement(94%), intravenous Amphotericin B(91%) and concomitant oral Posoconazole therapy(95.4%). 74.6% patients were discharged after clinical and radiologic recovery while 25.4% (15 patients) died. On Relative risk analysis, CT severity score during COVID-19 admission ≥18 (p=0.017), presence of orbital symptoms(p=0.002), presence of diabetic ketoacidosis(p=0.011) and cerebral involvement by Mucor(p=0.0004) were associated with increased risk of death. Duration of Amphotericin B therapy of ≥ 21 days was associated with statistically significant reduction in mortality(p=0.002).Conclusions CAM is an uncommon, rapidly progressive, angioinvasive, opportunistic fungal infection which is fatal if left untreated. Combination of surgical debridement and antifungal therapy leads to clinical and radiologic improvement in majority of cases.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRetrospective cohort study and hence clinical trial ID not takenFunding Statementthe authors or their institutions at any time have not received any external funding for any aspect of the submitted workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Noble hospital Institutional ethics committee, Noble hospital and Research Centre, Pune, India All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to the manuscript is available at Figshare https://figshare.com/s/b96305da2644d4b3de12 SARS-CoV-2Severe acute respiratory syndrome coronavirus 2COVID-19coronavirus disease 2019WHOWorld health organizationCAMCOVID-19 associated MucormycosisCRPC-reactive proteinLDHlactate dehydrogenaseIL-6Interleukin - 6IFN-γInterferon GammaDMdiabetes mellitusTCZTocilizumabCRScytokine release syndromeDKAdiabetic ketoacidosisROCMRhino-orbito-cerebral mucormycosisNHRCNoble hospital and Research CentreHRCTHigh resolution computerized tomography scanSpO2oxygen saturationPaO2/FiO2;ratio of arterial partial pressure of oxygen to fraction of inspired oxygenFESSFunctional endoscopic paranasal sinus surgeryLAm BLiposomal Amphotericin BRT-PCRreverse transcription PCRICUIntensive care unitCNSCentral nervous systemIRBinstitutional review boardIQRinterquartile rangeANCabsolute neutrophil countALCabsolute lymphocyte countIVIntravenousARDSacute respiratory distress syndrome